Want to use our logo?

Download the ICS Branding Pack

ICS Background

Dr Anthony John Kanai
University of Pittsburgh

ICS 2022

08 September 2022 07:30 Targeting Neurotrophin and Nitric Oxide Signalling to Promote Recovery and Ameliorate Neurogenic Bladder Dysfunction following Spinal Cord Injury—Mechanistic Concepts and Clinical Implications Targeting Neurotrophin and Nitric Oxide Signalling to Promote Recovery and Ameliorate Neurogenic Bladder Dysfunction following Spinal Cord Injury—Mechanistic Concepts and Clinical Implications

ICS 2021

17 October 2021 21:00 The Use of Novel Soluble Guanylate Cyclase Activators to Treat Benign Prostatic Hyperplasia, Obstruction and Fibrosis - Mechanistic Concepts and Clinical Implications The Use of Novel Soluble Guanylate Cyclase Activators to Treat Benign Prostatic Hyperplasia, Obstruction and Fibrosis - Mechanistic Concepts and Clinical Implications

ICS 2019

06 September 2019 11:30 W37 PDE5 Inhibitors and Novel Soluble Guanylate Cyclase Activators in the Treatment of Lower Urinary Tract Symptoms—Clinical Implications and Mechanistic Concepts

ICS 2018

28 August 2018 13:30 W13 Underactive Bladder—Clinical Implications, Mechanistic Concepts and Therapeutic Options

ICS 2017

12 September 2017 09:00 W8 Chronic Fibrosis in Lower Urinary Tract Dysfunctions—Mechanisms and Therapeutic Options

ICS 2011

30 August 2011 14:00 W43 New Aspects of Peripheral and Central Control of Micturition in the Overactive Bladder

ICS/IUGA 2010

24 August 2010 14:00 W47 Pathophysiological Mechanisms of Detrusor Overactivity and New Therapeutic Targets including Afferent Nerves, Interstitial Cells, Trigone and Urothelium.
 
View ICS Editorial Board Member Details

Anthony Kanai

ICS Editorial Board Member

Profession:Pharmacologist
Privacy:
You must be logged in to view this contact
Sign-in to ICS

Dr. Anthony Kanai is a tenured Professor of Medicine and Pharmacology & Chemical Biology at the University of Pittsburgh. His laboratory is funded by the National Institutes of Health and Department of Defense to study lower urinary tract dysfunctions (LUTDs) including underactive bladder (UAB), radiation cystitis and those due to spinal cord injury (SCI) and characterize new therapies. SCI induced LUTDs include detrusor overactivity (DO) and detrusor sphincter dyssynergia (DSD), with high risk complications including vesicoureteral reflux, obstructive uropathy and renal failure. Mainstay treatments include clean intermittent catheterization which circumvents DSD but often leads to urinary tract infections, and antimuscarinic agents, botulinum neurotoxins and neuromodulation which are effective against DO but not DSD. We have demonstrated that the small molecule p75 neurotrophin receptor modulator, LM11A-31, dampens DO and reverses DSD. We have also developed a mitochondrial targeting strategy for the free radical scavenger, XJB-5-131, that is radioprotective and was awarded two US Patents (7,718,603 and 9,402,839). We are also the first to demonstrate the expression of relaxin receptors 1 and 2 in bladder smooth muscle and that human relaxin-2 reverses bladder fibrosis by degrading excess collagen and stopping its further deposition. It also enhances detrusor contractility in UAB by increasing the expression of L-type calcium channels.

Dr Anthony John Kanai declared on the Wednesday 25th January 2023 that they had the following existing or known future financial relationships or affiliations:

National Institutes of Health

  • Research grant
UP TO DATE!